外显子
生物
癌症研究
腺癌
癌变
肺癌
选择性拼接
基因
遗传学
癌症
医学
病理
作者
Garrett Michael Frampton,Siraj Mahamed Ali,Mark Richard Rosenzweig,Juliann Chmielecki,Xinyuan Lu,Todd Michael Bauer,Mikhail Akimov,José A. Bufill,Carrie B. Lee,David Jentz,Rick Hoover,Sai‐Hong Ignatius Ou,Ravi Salgia,Timothy J. Brennan,Zachary Rockow Chalmers,Savina A. Jaeger,Alan Huang,Julia Andrea Elvin,Rachel Erlich,Alex Fichtenholtz
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2015-05-13
卷期号:5 (8): 850-859
被引量:818
标识
DOI:10.1158/2159-8290.cd-15-0285
摘要
UNLABELLED: Focal amplification and activating point mutation of the MET gene are well-characterized oncogenic drivers that confer susceptibility to targeted MET inhibitors. Recurrent somatic splice site alterations at MET exon 14 (METex14) that result in exon skipping and MET activation have been characterized, but their full diversity and prevalence across tumor types are unknown. Here, we report analysis of tumor genomic profiles from 38,028 patients to identify 221 cases with METex14 mutations (0.6%), including 126 distinct sequence variants. METex14 mutations are detected most frequently in lung adenocarcinoma (3%), but also frequently in other lung neoplasms (2.3%), brain glioma (0.4%), and tumors of unknown primary origin (0.4%). Further in vitro studies demonstrate sensitivity to MET inhibitors in cells harboring METex14 alterations. We also report three new patient cases with METex14 alterations in lung or histiocytic sarcoma tumors that showed durable response to two different MET-targeted therapies. The diversity of METex14 mutations indicates that diagnostic testing via comprehensive genomic profiling is necessary for detection in a clinical setting. SIGNIFICANCE: Here we report the identification of diverse exon 14 splice site alterations in MET that result in constitutive activity of this receptor and oncogenic transformation in vitro. Patients whose tumors harbored these alterations derived meaningful clinical benefit from MET inhibitors. Collectively, these data support the role of METex14 alterations as drivers of tumorigenesis, and identify a unique subset of patients likely to derive benefit from MET inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI